See other companies on Welcome to the Jungle
CHARM Therapeutics
3D deep learning technology for medicine
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Deep Tech
- Westminster, London, UK
Jump to section
Company mission
Unfolding the future of medicine through 3D deep learning technology.
Our take
Demand for treatments for diseases such as cancer are in high demand, but identifying new drugs is an expensive and time-consuming process. CHARM Therapeutics leverages the power of deep learning for drug discovery.
CHARM Therapeutics is headed up by a team with impressive experience in the fields of AI and protein research. This expertise has garnered the company significant attention, culminating in a $50 million series A round in 2022 and a $20 million VC round the following year. This funding is a clear testament to the company's potential.
CHARM Therapeutics is one of a raft of new companies exploring the ways in which AI can transform drug discovery. However, it has set itself apart with its focus on small molecule treatments. This distinction will prove invaluable as the company looks to secure further funding.
Steph
Company Specialist at Welcome to the Jungle
Funding (last 2 of 3 rounds)
Apr 2023
$20m
EARLY VC
Jun 2022
$50m
SERIES A
Total funding: $82.6m
This company has top investors
Leadership
Laksh Aithani
(CEO)Previously worked as a Machine Learning Engineer at Exscientia, and as Founder of genei.
David Baker
(Scientific Co-Founder)Previously co-founded SANA Biotechnologies, Lyell Immunopharma and Icosavax. Currently serves as Director of the Institute for Protein Design.